EUVIMEDEUVIMED entdecken
Crossref

The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Khalid Al Hinai iD, Sara Al Jahwari iD, Manar Nassr iD

Journal of Surgical Oncology · 14.11.2026

DOI: 10.1002/jso.70454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 14.11.2026. Verfasst von Khalid Al Hinai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Oman Medical Specialty Board, Muscat, Sultanate of Oman. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival in selected patients with colorectal peritoneal metastases. However, outcomes remain heterogeneous, and tumor molecular biology may influence prognosis.

Methods

We retrospectively reviewed patients with colorectal cancer and peritoneal metastases treated with CRS and HIPEC at Royal Hospital between May 2013 and August 2024. Patients were grouped by presence of genetic mutations (GM) versus no mutations (no‐GM). Primary outcomes were overall survival (OS) and recurrence‐free survival (RFS). Secondary outcomes included morbidity and prognostic factors for recurrence.

Results

Among 159 patients, 73 (45.9%) had a documented genetic mutation. Genetic mutation was associated with a shorter median RFS (8 months in the GM group vs. 27 months in the no‐GM group; p < 0.001), with 5‐year RFS of 6.0% and 45.3%, respectively. Genetic mutation was also associated with a shorter median OS on univariable analysis (37 months vs. not reached; p = 0.001). On multivariable analysis, genetic mutation status (HR 3.821, 95% CI 2.270–6.432; p < 0.001), PCI > 15 (HR 1.073; p = 0.005), and pre‐HIPEC chemotherapy (HR 2.194; p = 0.003) were independently associated with recurrence. For OS, PCI (HR 1.066; p = 0.037) and poorly differentiated tumor grade (HR 2.946; p = 0.045) were independently associated with survival, whereas genetic mutation status was not (HR 1.477; p = 0.197).

Conclusion

Genetic mutation was associated with shorter RFS after CRS and HIPEC, and this association persisted after multivariable adjustment. The association with OS was not independent of PCI and tumor grade, suggesting that disease burden may be the main driver of survival. Molecular status may complement established clinicopathological factors in patient assessment; larger prospective studies stratified by mutation type are needed.

Schlagwörter

Stichwörter der Autor:innen

BRAFHIPECKRAScolorectal cancercytoreductive surgeryperitoneal metastasesprognosis

Autor:innen und Institutionen

  • Oman Medical Specialty Board, Muscat, Sultanate of Oman.
  • General Surgery Department, Royal Hospital, Muscat, Sultanate of Oman.
  • Royal Hospital, Muscat, Sultanate of Oman.

ORCID-Profile: Khalid Al Hinai, Sara Al Jahwari, Manar Nassr

Zitieren

APA

Hinai, K. A., Jahwari, S. A., & Nassr, M. (2026). The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Oncology. https://doi.org/10.1002/jso.70454

Vancouver

Hinai KA, Jahwari SA, Nassr M. The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Surgical Oncology. 2026. doi:10.1002/jso.70454

BibTeX
@article{Hinai2026,
  author = {Hinai, Khalid Al and Jahwari, Sara Al and Nassr, Manar},
  title = {The Impact of Tumor Molecular Profile on Prognosis for Patients With Peritoneal Metastases From Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  doi = {10.1002/jso.70454}
}
Kostenlos starten →